Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rite Aid-drugstore.com OTC site

This article was originally published in The Tan Sheet

Executive Summary

Drugstore.com will host an online Rite Aid OTC store slated to launch this year, the companies say Sept. 4. Camp Hill, Pa.-based Rite Aid will receive rights to all Rx drugs ordered online for in-store pickup and will pay drugstore.com $10 million. "Having our own online OTC store and being able to market directly" to the pharmacy chain's customer base "is an important next step in our digital strategy," says Rite Aid Chief Operating Officer Rob Easley. Dawn Lepore, CEO of Bellevue, Wash.-based drugstore.com, says she expects increased sales as "Rite Aid will develop marketing programs to drive traffic to the new site." The e-retailer's 2007 net sales, announced in February, were below expectations due to increased marketing costs (1"The Tan Sheet" Feb. 11, 2008, In Brief)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102081

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel